KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dynavax Technologies (DVAX) Accumulated Expenses: 2009-2024

Historic Accumulated Expenses for Dynavax Technologies (DVAX) over the last 16 years, with Dec 2024 value amounting to $61.1 million.

  • Dynavax Technologies' Accumulated Expenses fell 4.09% to $51.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.9 million, marking a year-over-year decrease of 4.09%. This contributed to the annual value of $61.1 million for FY2024, which is 23.50% up from last year.
  • As of FY2024, Dynavax Technologies' Accumulated Expenses stood at $61.1 million, which was up 23.50% from $49.4 million recorded in FY2023.
  • In the past 5 years, Dynavax Technologies' Accumulated Expenses ranged from a high of $61.1 million in FY2024 and a low of $19.1 million during FY2020.
  • Moreover, its 3-year median value for Accumulated Expenses was $49.4 million (2023), whereas its average is $47.1 million.
  • Per our database at Business Quant, Dynavax Technologies' Accumulated Expenses spiked by 160.73% in 2021 and then slumped by 38.31% in 2022.
  • Dynavax Technologies' Accumulated Expenses (Yearly) stood at $19.1 million in 2020, then spiked by 160.73% to $49.8 million in 2021, then tumbled by 38.31% to $30.7 million in 2022, then surged by 60.97% to $49.4 million in 2023, then rose by 23.50% to $61.1 million in 2024.